A phase I study of CR002, a fully-human monoclonal antibody against platelet-derived growth factor-D

International Journal of Clinical Pharmacology and Therapeutics

Volumn 46, Issue 5, 2008, Pages 236-244

  Hawthorne, T ^a   Giot, L ^a   Blake, L ^a   Kuang, B ^a   Gerwien, R ^a   Smithson, G ^a   Hahne, W ^a   Mansfield, T ^a   Starling, G C ^a   Pochart, P ^a   Hoelscher, D ^b   Halvorsen, Y D ^a  

^a CURAGEN CORPORATION   (United States)

^b Pharmaceutical Product Development   (United States)

Author keywords

CR002; Monoclonal antibody drug; PDGF D; Pharmacodynamics; Pharmacokinetics

Indexed keywords

IMMUNOGLOBULIN G2 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CR 002; PLACEBO; PLATELET DERIVED GROWTH FACTOR D;

ADULT; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ELECTROCARDIOGRAM; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; LABORATORY TEST; LIBIDO; LOW DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; NORMAL HUMAN; NOSE CONGESTION; PATIENT MONITORING; RHINORRHEA; SIDE EFFECT; SINGLE DRUG DOSE; THIRST; THROAT IRRITATION; UNSPECIFIED SIDE EFFECT; VITAL SIGN;

EID: 43449098197     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP46236     Document Type: Article

References (16)